EGRX - イ―グル・ファ―マシュ―ティカルズ (Eagle Pharmaceuticals Inc.) イ―グル・ファ―マシュ―ティカルズ

 EGRXのチャート


 EGRXの企業情報

symbol EGRx
会社名 Eagle Pharmaceuticals Inc. (イ―グル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 イーグル・ファーマスーティカルス(Eagle Pharmaceuticals Inc.)は専門の製薬会社。同社は救命救急診療と腫瘍分野での注射用製品の開発と製品化を行う。同社の製品ポートフォリオはアルガトロバン、Ryanodex、ドセタキセル注射剤、非アルコール製剤、ベンデカを含む。同社の上級候補製品はベンダムスチン抵抗値温度検出器(RTD)EP-3101、熱中症用のダントロレンナトリウム(EHS)EP-4104、薬物誘発性高体温用のダントロレンナトリウムEGL-4104-C-1702、ペメトレキセドEP-5101、フルベストラントEGL-5385-C-1701。同社の製品ポートフォリオはがん治療、救急医療、希少疾病に注目する。ベンダムスチンは、リツキシマブまたはリツキシマブ含有レジメンによる治療の6カ月または6カ月以内に進行した慢性リンパ球性白血病(CLL)および無痛性B細胞非ホジキンリンパ腫(NHL)に使用が認可されるアルキル化剤である。   イ―グル・ファ―マシュ―ティカルズは米国の特殊医薬品会社。米国食品医薬品局(FDA)の505(b)(2)による規制手順を活用して、主に救命救急及び腫瘍学分野の注射製剤の開発・商業化に重点を置く。先進的な製品には、悪性高熱症のための懸濁注射剤「Ryanodex」がある。本社はニュ―ジャ―ジ―州。   Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
本社所在地 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 USA
代表者氏名 Michael Graves マイケル・グレイブス
代表者役職名 Independent Chairman of the Board
電話番号 +1 201-326-5300
設立年月日 39083
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 108人
url www.eagleus.com
nasdaq_url https://www.nasdaq.com/symbol/egrx
adr_tso
EBITDA EBITDA(百万ドル) 59.09800
終値(lastsale) 63.42
時価総額(marketcap) 954846700.08
時価総額 時価総額(百万ドル) 948.07150
売上高 売上高(百万ドル) 215.72800
企業価値(EV) 企業価値(EV)(百万ドル) 894.54250
当期純利益 当期純利益(百万ドル) 33.19100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eagle Pharmaceuticals Inc revenues decreased 17% to $105.9M. Net income decreased 81% to $5.3M. Revenues reflect License and other income decrease from $25M to $0K Royalty revenue decrease of 3% to $72M. Net income also reflects Research and development - Balancing val increase from $10.1M to $27.5M (expense) IE on Capital Financing Gross increase from $67K to $1.4M (expense).

 EGRXのテクニカル分析


 EGRXのニュース

   Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences  2020/09/08 10:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming conferences in September. At the Morgan Stanley 18th Annual Virtual Global Healthcare Conference: Date: Monday, September 14, 2020 Time: 3:00 p.m. Eastern Time Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1362588&tp_key=91c8ad632b At the
   Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease  2020/08/19 10:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did
   The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, Biotech IPOs  2020/08/16 12:30:58 Benzinga
Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) and Fennec Pharmaceuticals Inc (NASDAQ: FENC ) received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Inc's (NASDAQ: ETON ) eye inflammation drug hadn't come by the Aug. 10 decision date. The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals. Here are the key catalysts for the unfolding week. Conferences Virtual Keystone Symposia: Advances in Cancer Immunotherapy: Aug. 17-19 PDUFA Dates Gilead Sciences, Inc. (NASDAQ: GILD ) and licensing partner GALAPAGOS NV/S ADR (NASDAQ: GLPG ) await FDA decision on the NDA for filgotinib in moderate-to-severe rheumatoid arthritis. (estimated date of Wednesday, Aug. 19, assuming priority … Full story available on Benzinga.
   Eagle Pharmaceuticals Reports Second Quarter 2020 Results  2020/08/10 10:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2020. Business and Recent Highlights: Centers for Medicare & Medicaid Services (“CMS”) established unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-code, for PEMFEXY™ (Pemetrexed for Injection, 10 mg), a branded alternative to ALIMTA® effective October 1, 2020; Granted a supplement appr
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus  2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
   Eagle Pharmaceuticals to Present at June Investor Conferences  2020/05/26 20:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Jefferies Virtual Healthcare Conference Date: Thursday, June 4, 2020 Time: 1:00 p.m. ET Webcast: http://wsw.com/webcast/jeff126/egrx/ Conference: William Blair Virtual 40th Annual Growth Stock Conference Date: T
   Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders  2020/05/22 20:05:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio we
   Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference  2020/05/12 20:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference as follows: Date: Tuesday, May 19, 2020 Time: 3:05 p.m. Eastern Time Webcast: https://www.veracast.com/webcasts/rbc/healthcare2020/01112239705.cfm The presentation will be webcast live a
   Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates  2020/05/11 12:35:04 Zacks Investment Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Eagle Pharmaceuticals to Present at June Investor Conferences  2020/05/26 20:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Jefferies Virtual Healthcare Conference Date: Thursday, June 4, 2020 Time: 1:00 p.m. ET Webcast: http://wsw.com/webcast/jeff126/egrx/ Conference: William Blair Virtual 40th Annual Growth Stock Conference Date: T
   Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders  2020/05/22 20:05:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio we
   Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference  2020/05/12 20:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference as follows: Date: Tuesday, May 19, 2020 Time: 3:05 p.m. Eastern Time Webcast: https://www.veracast.com/webcasts/rbc/healthcare2020/01112239705.cfm The presentation will be webcast live a
   Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates  2020/05/11 12:35:04 Zacks Investment Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Fed Circuit okays generic version of Eagle Pharma chemotherapy drug  2020/05/08 20:43:42 Reuters
Generic drug company Slayback Pharma LLC on Friday won an appeals court decision that clears the way for it to launch a generic version of the Eagle Pharmaceuticals Inc chemotherapy drug Belrapzo.

 関連キーワード  (医薬品 米国株 イ―グル・ファ―マシュ―ティカルズ EGRX Eagle Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)